Health Condition 1: L959- Vasculitis limited to the skin, unspecified
Conditions
Interventions
None listed
Sponsors
GCS Medical College Hospital and Research Centre
Eligibility
Inclusion criteria
Inclusion criteria: Patients of either sex and of all age group. Patient presenting clinical sign and symptoms suggestive of cutaneous vasculitis or vasculopathy like, 1) Palpable purpura 2) Petechiae 3) Macular purpura 4)Urticarial papules 5) Vesicles 6)Pustules 7)Targeted papules and plaques 8) Livedo racemosa 9)Retiform purpura 10)Ulcers 11)Subcutaneous nodules 12)Digital necrosis 13)Erythema 14)Cyanotic skin 15)Livedo reticularis 16)Atrophie blanche 17)Ecchymotic streak 18)Any other on PI discretion.
Exclusion criteria
Exclusion criteria: 1)All patient not willing to give consent 2)Any systemic vascultis case without cutaneous manifestations. Patients having pre-existing or detected during study work up any other disease which mimic cutaneous vasculitis and diseases involving vessel walls other than livido vasculopathy and malignant atrophic papulosis will be excluded from final analysis. Following is list of such disorders.( this is not definite list any other compounding factor on PI discretion will be excluded from final analysis.) 3)Patient with hemostatically relevant thrombocytopenia (<50,000/cu mm) in following condition: Idiopathic thrombocytopenic purpura Thrombotic thrombocytopenic purpura Disseminated intravascular coagulation Thrombocytopenia due to 1) drug related peripheral destruction (eg quinine, quinidine) 2) Drug induced decreased production, idiosyncratic or dose related (eg chemotherapy) 3) Bone marrow infiltration, fibrosis or failure 4) Patient with congenital or hereditary platelet function defects 5)Patient with acquired platelet function defects due to 1) Aspirin, NSAIDs 2) Renal insufficiency 3) Monoclonal gammopathy 6)Patient with thrombocytosis secondary to myeloproliferative disorders (often >1000000/cu mm) 7)Patient with occlusion primarily due to microvascular platelet plugs like heparin necrosis 8)Patient with cold related gelling or agglutination like in 1)cryoglobulinemia , monoclonal 2) cryofibrinogenemia 3) cold agglutinins 9)Patient with vessel â?? invasive fungi 10)Patient with ecthyma gangrenosum • Patient with disseminated strongyloidiasis 12)Patient with Protein C and S related 1) Homozygus protein C or protein S deficiency 2) Acquired protein C deficiency 3) Coumadin /Warfarin necrosis (protein C dysfunction) 4) post infectious purpura fulminans (protein S dysfunction) 13) Patient with antiphospholipid antibody,lupus anticoagulant • Patient with Sneddon syndrome (vascular coagulopathy) 15)Patient with embolization or crystal deposition like 1) cholesterol emboli 2) oxalate crystal deposition 3) marantic endocarditis, atrial myxoma, crystal globulins, hypereosinophilic syndrome 16)Patient with high reticulocyte states like sickle cell disease, other severe hemolytic anemias, severe malaria 17)Patient with cutaneous calciphylaxis, Brown recluse spider bite reaction , Intravascular B cell lymphoma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To study Clinical spectrum of disease under cutaneous vascultis and vasculopathy â?¢ To study pathological finding of disease under cutaneous vascultis and vasculopathy â?¢ To study clinic-histopathological correlation of cutaneous vasculitis and vasculopathy. â?¢ To study DIF finding in disease under cutaneous vasculitis and vasculopathy â?¢ To study systemic involvement in cases of cutaneous vascultis and vasculopathy.Timepoint: 2 Years | — |
Secondary
| Measure | Time frame |
|---|---|
| To study biomarkers association if any of cutaneous vasculitis and vasculopathy.Timepoint: 2 Years | — |
Countries
India
Contacts
Public ContactDr Nayan Patel
GCS Medical College, Hospital and Research Centre
Outcome results
None listed